# Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia

> **NCT07723716** · PHASE3 · COMPLETED · sponsor: **Taejoon Pharmaceutical Co., Ltd.** · enrollment: 167 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** CTO0307 Eye drop
- **DRUG:** Vehicle (Placebo solution)

## Key facts

- **NCT ID:** NCT07723716
- **Lead sponsor:** Taejoon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-26
- **Primary completion:** 2025-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2026-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723716, "Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07723716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*